Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06804824 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by Vividion Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 220
- Enrollment target
- 9
- Study locations
NCT06804824: Recruiting Phase 1 study of Advanced Solid Tumors, sponsored by Vividion Therapeutics.
NCT06804824 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by Vividion Therapeutics. The registered enrollment target is 220 participants, above the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (12% higher). The trial reports 9 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06804824, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by Vividion Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 220 participants
- Enrollment target
- 9
- Study locations
Study Summary
A FIH study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of VVD-159642, a rat sarcoma viral oncogene-phosphatidylinositol 3-kinase alpha (RAS-PI3Kα) inhibitor, as a single agent and in combination with either sotorasib or trametinib in participants with advanced solid tumors.
Conditions Studied
Interventions
- DRUG Trametinib
- DRUG Sotorasib
- DRUG VVD-159642
Study Locations (9)
Texas
- NEXT Austin - Austin
- NEXT Dallas - Irving
- START San Antonio - San Antonio
- NEXT San Antonio - San Antonio
Michigan
- START Mid West - Grand Rapids
Utah
- START Mountain - Ogden
Virginia
- NEXT Virginia - Fairfax
South Australia
- Clinical Research South Australia (CRSA) - Adelaide
Western Australia
- Linear Clinical - Nedlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2025-02-25 |
| Est. Completion | 2027-08-01 |
| Phase | Phase 1 |
What NCT06804824 shows while recruiting
NCT06804824 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, above the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (12% higher).
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which Trametinib is the first listed.
NCT06804824 lists 9 locations in 6 states (Texas, Michigan, Utah).
Frequently Asked Questions
What is clinical trial NCT06804824 about?
NCT06804824 is a clinical study titled "A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors". A FIH study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of VVD-159642, a rat sarcoma viral oncogene-phosphatidylinositol 3-kinase alpha (RAS-PI3Kα) inhibitor, as a single agent and in combination with either sotorasib or tra...
What is the current status of trial NCT06804824?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 220 participants. The study started on 2025-02-25. Estimated completion is 2027-08-01.
What conditions does trial NCT06804824 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT06804824?
The interventions under investigation include: Trametinib (DRUG), Sotorasib (DRUG), VVD-159642 (DRUG).
Who is sponsoring clinical trial NCT06804824?
This trial is sponsored by Vividion Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06804824 being conducted?
This trial has 9 study locations across Michigan, Texas, Utah, Virginia, South Australia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06804824's enrollment target sits among peer trials
220 40th of 144 higher than 105 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI